ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

Dusunen Adam. 2013; 26(1): 106-110


Single dose olanzapin-induced fatal neuroleptic malignant syndrome: a case report

Hatice Harmancı, Serap Erdoğan Taycan.




Abstract

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal idiosyncratic reaction characterized by the development of altered consciousness, hyperthermia, autonomic dysfunction, and muscular rigidity on exposure to neuroleptic medications. NMS commonly develops during the initial phases of treatment, when the drug dose is being stepped up, or when a second drug is introduced. Although various risk factors have been proposed, the exact etiology is unknown. The mortality and morbidity associated with NMS can be decreased with early recognition, early discontinuation of the neuroleptics and aggressive treatment. In this case report, a schizophrenia patient who developed NMS without hyperthermia and obvious autonomic dysfunction after single use of olanzapine will be discussed. His symptoms of loss of consciousness, dystonia and urinary and fecal incontinence continued and 6 months later, he died due to cardiopulmonary arrest.

Key words: Neuroleptic malignant syndrome, olanzapine, sequelae, death





11
14
12
10
11
18
16
18
20
25
36
18
37
6
2024-032024-042024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-04

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.


We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More Info Got It!